<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The prognostic potential of KRAS mutations in advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients and the impact of KRAS mutation status on the effectiveness of chemotherapy or vascular endothelial growth factor (VEGF) signalling inhibitor therapy remain unclear </plain></SENT>
<SENT sid="1" pm="."><plain>KRAS mutation status was evaluated retrospectively as a potential prognostic/predictive marker of clinical outcomes using <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> samples from patients with metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> receiving cediranib or placebo plus FOLFOX/XELOX in a Phase III trial (HORIZON II; NCT00399035) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: KRAS codon 12 and 13 mutation analyses were performed using a commercially available, allele-specific, amplification refractory mutation system (ARMS)-based polymerase chain reaction (PCR) assay </plain></SENT>
<SENT sid="3" pm="."><plain>Retrospective analyses of progression-free survival (PFS) and overall survival (OS) according to KRAS mutation status were performed for patients randomised to cediranib 20mg or placebo </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: KRAS status was determined in 599/1076 patients (cediranib 20mg, n=285/502; cediranib 30mg, n=110/216; placebo, n=204/358) </plain></SENT>
<SENT sid="5" pm="."><plain>Baseline characteristics were similar across KRAS mutant (n=258; 24.0%), <z:mp ids='MP_0002169'>wild-type</z:mp> (n=341; 31.7%) and status unknown (n=477; 44.3%) groups </plain></SENT>
<SENT sid="6" pm="."><plain>There was a trend towards improved PFS and OS in the <z:mp ids='MP_0002169'>wild-type</z:mp> versus mutant subgroups independent of treatment (cediranib 20mg and placebo: PFS hazard ratio (HR)=0.85 [median PFS: <z:mp ids='MP_0002169'>wild-type</z:mp>=8.5months; mutant=8.3months]; OS HR=0.71 [median OS: <z:mp ids='MP_0002169'>wild-type</z:mp>=20.9months; mutant=16.9months]) </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment effects were similar between KRAS subgroups for cediranib 20mg versus placebo (PFS: <z:mp ids='MP_0002169'>wild-type</z:mp> HR=0.78, mutant HR=0.82; OS: <z:mp ids='MP_0002169'>wild-type</z:mp> HR=0.92, mutant HR=1.01) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Data from this large randomised Phase III study show that KRAS codon 12/13 mutations have negative prognostic value in metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients receiving treatment with FOLFOX/XELOX, but KRAS mutation status is not predictive of treatment benefit with cediranib, using PFS or OS </plain></SENT>
</text></document>